Abstract:BACKGROUND:The sixth leading class of cancer worldwide is head and neck cancer, which typically arise within the squamous epithelium of the oral mucosa. Human head and neck squamous cell carcinoma (HNSCC) is known to be difficult to treat and has only a 50% five-year survival rate. With HNSCC, novel therapeutics are needed along with a means of rapidly screening anti-cancer agents in vivo, such as mouse models.METHODS:In order to develop new animal models of cancer to test safety and efficacy of novel therapeutic agents for human HNSCC, tumors resembling clinical cases of human HNSCC were induced in the head and neck epithelium of a genetically engineered mouse model. This mouse model was generated by conditional deletion of two tumor suppressors, Transforming Growth Factor-β Receptor 1 (TGFβRI) and Phosphatase and Tensin homolog (PTEN), in the oral epithelium. We discovered that the tumors derived from these Tgfbr1/Pten double conditional knockout (2cKO) mice over-expressed IL-13Rα2, a high affinity receptor for IL-13 that can function as a tumor antigen. To demonstrate a proof-of-concept that targeted therapy against IL-13Rα2 expression would have any antitumor efficacy in this spontaneous tumor model, these mice were treated systemically with IL-13-PE, a recombinant immunotoxin consisting of IL-13 fused to the Pseudomonas exotoxin A.RESULTS:Tgfbr1/Pten 2cKO mice when treated with IL-13-PE displayed significantly increased survival when compared to the untreated control mice. The untreated mice exhibited weight loss, particularly with the rapid onset of tongue tumors, but the treated mice gained weight while on IL-13-PE therapy and showed no clinical signs of toxicity due to the immunotoxin. Expression of IL-13Rα2 in tumors was significantly decreased with IL-13-PE treatment as compared to the controls and the number of myeloid-derived suppressor cells (MDSC) was also significantly reduced in the spleens of the IL-13-PE treated mice.CONCLUSIONS:Our study demonstrates that the Tgfbr1/Pten 2cKO mouse model of human HNSCC is a useful model for assessing antitumor activity of new cancer therapeutic agents, and that IL-13-PE has therapeutic potential to treat human head and neck cancer.

Mouse Interleukin-2 Gene Therapy for Head Andneck Squamous Cell Carcinoma by Polycationicliposome-Mediated Transfection

Studies of Mouse Interleukin-2 Gene Therapy for Head and Neck Sequamous Cell Carcinoma Using Polycationic Liposome-mediated Transduction

Combined IL-2 and IL-12 Gene Therapy for Murine Head and Neck Squamous Cell Carcinoma.

[Antitumour Study with Combined IL-2 Gene Therapy and Radiation for Head and Neck Squamous Cell Carcinoma].

ANTITUMOR EFFECTS OF HUMAN IL-15 GENE MODIFIED LUNG CANCER CELL LINE

Combination Radiation and Gene Therapy for Head and Neck Squamous Cell Carcinoma in the Murine Model

[Combined Interleukin-2 and Herpes Simplex Virus Thymidine Kinase Gene Therapy for Head and Neck Squamous Cell Carcinoma].

Combination Nonviral Murine Interleukin 2 And Interleukin 12 Gene Therapy And Radiotherapy For Head And Neck Squamous Cell Carcinoma

[Therapeutic effect of cationic liposome-mediated interleukin-12 gene delivery on murine melanoma in vivo].

Antitumor Effects Obtained by Autologous Lewis Lung Cancer Cell Vaccine Engineered to Secrete Mouse Interleukin 27 by Means of Cationic Liposome.

Antitumor effect of gene therapy with recombinant adenovirus-mediated human interleukin-2 gene transfer and its mechanism]

Antitumor Effects Of Interleukin-18 Gene-Modified Hepatocyte Cell Line On Implanted Liver Carcinoma

Targeting of Interleukin-13 Receptor Α2 for Treatment of Head and Neck Squamous Cell Carcinoma Induced by Conditional Deletion of TGF-β and PTEN Signaling

[Establishment of a SCID Mouse Model for Synergistic Anti-Tumor Effect of Human IL-12 and B7-1].

Preliminary Study on Mouse Interleukin-21 Application in Tumor Gene Therapy.

Local and Systemic Delivery of Interleukin-12 Gene by Cationic Micelles for Cancer Immunogene Therapy.

Gene Therapy with Tumor-Specific Promoter Mediated Suicide Gene Plus IL-12 Gene Enhanced Tumor Inhibition and Prolonged Host Survival in a Murine Model of Lewis Lung Carcinoma

Antagonism Between Gene Therapy and Epigenetic Therapy on Human Laryngeal Carcinoma Tumor-Bearing Mice

[Study on the Effects of Combined IL-12 and GM-CSF Gene Therapy for Murine Liver Cancer].

Antitumoral Efficacy By Systemic Delivery Of Heparin Conjugated Polyethylenimine-Plasmid Interleukin-15 Complexes In Murine Models Of Lung Metastasis

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles